A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non–Small-Cell Lung Cancer Patients.pdfVIP

Original Study A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in NoneSmall-Cell Lung Cancer Patients Kazuki Takada,1,2 Gouji Toyokawa,1 Tatsuro Okamoto, 1 Mototsugu Shimokawa,3 Yuka Kozuma, 1 Taichi Matsubara, 1 Naoki Haratake,1 Takaki Akamine,1 Shinkichi Takamori,1 Masakazu Katsura,1 Fumihiro Shoji,1 Yoshinao Oda,2 Yoshihiko Maehara 1 Abstract We examined programmed cell death ligand-1 (PD-L1) expression in 499 surgically resected nonesmall-cell lung cancer (NSCLC) patients using the clone SP142 and 4 different cutoff values. PD-L1 expression in NSCLC was shown to vary greatly according to different cutoff values, and to be associated with poor survival in NSCLC patients. This study might be a useful reference to understand the results of the POPLAR and OAK studies. Background: Programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have been identified as novel targets for immunotherapy, with antiePD-1 therapy currently the standard treatment for nonesmall-cell lung cancer (NSCLC) patients after the failure of first-line chemotherapy treatment. The recent phase II POPLAR and phase III OAK studies showed that atezolizumab, a representative PD-L1 inhibitor, exhibited a survival benefit compared with standard therapy in patients with NSCLC. Patients and Methods: We examined PD-L1 expression in NSCLC using the clone SP142 of POPLAR and OAK studies. PD-L1 expression in 499 surgically resected NSCLC patients was